#USA #Fremont #Alamar Biosciences #NULISA #Biomarker Detection

Alamar Biosciences Launches Certified Service Provider Program

Alamar Biosciences, a front-runner in precision proteomics aimed at early disease detection, has recently unveiled its Certified Service Provider (CSP) Program. This innovative initiative seeks to enhance accessibility to Alamar's cutting-edge NULISA™ assays for both academic and biopharmaceutical researchers. With the demand for high-sensitivity protein detection surging, this program provides an essential resource for scientists pursuing groundbreaking research.

NULISA™ Platform Overview

Alamar's NULISA™ Platform sets a new benchmark in proteomic analysis with its unparalleled attomolar sensitivity. The platform allows researchers to detect and quantify biomarkers with remarkable precision, addressing a wide array of applications. The launch of the CSP Program is aligned with Alamar's mission to support research initiatives and promote advancements in scientific discovery.

The CSP Program affords researchers a scalable and cost-effective means of engaging with Alamar's NULISA technology. By collaborating with skilled service providers, Alamar aims to empower scientists with expanded opportunities and access to world-class analytical capabilities.

Certified Service Providers

As of now, six distinguished laboratories have attained CSP certification and are actively working on various projects. These include:

• - Biognosys (Switzerland/USA): Known for its specialty proteomics as a contract research organization (CRO), Biognosys delivers precise proteome quantification through mass spectrometry and multiplex assays. Their services range from biomarker discovery to monitoring in clinical trials.
• - Banner Health (Arizona, USA): This institution specializes in research services focusing on neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.
• - Emtherapro (Georgia, USA): Emtherapro is dedicated to advancing the discovery and validation of novel biomarkers, which play a crucial role in risk profiling, diagnosis, and monitoring.
• - ESYA Labs (UK/USA): They provide multi-modal diagnostic solutions specifically aimed at brain health screening, ensuring comprehensive assessment capabilities.
• - Frontage Labs: Offers expertise in biomarker assay development, validation, and comprehensive sample analysis, lending additional support to researchers' projects.
• - Sapient (San Diego, USA): This lab provides an extensive array of multi-omics solutions incorporating proteomics, metabolomics, and lipidomics, which facilitate target identification and the discovery of biomarkers.

A Commitment to Research Excellence

Dr. Yuling Luo, the Founder, Chairman, and CEO of Alamar Biosciences, expressed enthusiasm regarding the launch of the CSP Program. “We are thrilled to make our NULISA technology more accessible to the research community. By collaborating with these trusted service providers, we are ensuring that researchers have the support and expertise they need to drive groundbreaking discoveries in protein biomarker research,” he stated.

The CSP Program is a notable stride towards fulfilling Alamar’s objective of propelling scientific progress through innovative assay solutions. Researchers participating in the program can confidently execute their projects knowing they are collaborating with certified labs that comply with Alamar's stringent quality and performance standards.

About Alamar Biosciences

Alamar Biosciences operates as a private life sciences entity committed to advancing precision proteomics for the earliest disease detection. Utilizing its proprietary NULISA™ Platform along with the ARGO™ HT System, the company achieves single-digit attomolar detection sensitivity, significantly surpassing other protein detection technologies available today. To learn more about Alamar's offerings, visit alamarbio.com.